Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo

Hepatocellular carcinoma (HCC) is the sixth most frequent malignant tumor with poor prognosis, and its clinical therapeutic outcome is poor. Volasertib, a potent small molecular inhibitor of polo-like kinase 1 (PLK1), is currently tested for treatment of multiple cancers in the clinical trials. Howe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Am J Cancer Res
Egile Nagusiak: Zheng, Di-Wei, Xue, You-Qiu, Li, Yong, Di, Jin-Ming, Qiu, Jian-Ge, Zhang, Wen-Ji, Jiang, Qi-Wei, Yang, Yang, Chen, Yao, Wei, Meng-Ning, Huang, Jia-Rong, Wang, Kun, Wei, Xing, Shi, Zhi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: e-Century Publishing Corporation 2016
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5126267/
https://ncbi.nlm.nih.gov/pubmed/27904765
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak